ABBV vs DMAC · P/E 81, rev $61.16B vs $157.4M cap
AbbVie Inc (ABBV) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
DMAC does not have a complete income-statement cache yet.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the ABBV and DMAC stock pages for the full models.
Not investment advice.